The 5 Most Common Antimalarial Drugs (And How They Work)

Antimalarial drugs are prescription medications used to prevent or treat malaria, a life-threatening disease transmitted by Anopheles mosquitoes infected with Plasmodium parasites. The main classes include artemisinin-based combination therapies (ACTs), chloroquine, and prophylactic drugs like atovaquone-proguanil and doxycycline. These drugs work by targeting the parasite at different stages of its life cycle inside the human body. According to the World Health Organization’s 2024 World Malaria Report, there were an estimated 249 million malaria cases globally in 2023, with ACTs remaining the first-line treatment for uncomplicated P. falciparum malaria. Last updated: June 2026 — updated to reflect 2025-2026 research on emerging drug resistance and West Nile virus co-occurrence.

What Is Anti Malarial Drugs?

Antimalarial drugs are pharmaceutical agents specifically designed to prevent or treat malaria infection caused by Plasmodium parasites. The most effective modern treatments are artemisinin-based combination therapies (ACTs), which combine a fast-acting artemisinin derivative with a longer-acting partner drug to reduce the risk of resistance. According to the U.S. Centers for Disease Control and Prevention’s 2025 Yellow Book, chloroquine remains effective only in limited regions due to widespread resistance, while atovaquone-proguanil (brand name Malarone) and doxycycline are preferred for prophylaxis in most endemic areas. The drugs work by interfering with the parasite’s ability to digest hemoglobin, replicate, or survive inside red blood cells. The World Health Organization’s 2025 Malaria Treatment Guidelines classify antimalarials into three categories: blood schizonticides (ACTs, chloroquine), tissue schizonticides (primaquine), and prophylactic agents (atovaquone-proguanil, doxycycline, mefloquine).

What Are the Main Types of Antimalarial Drugs and How Do They Compare?

The choice of antimalarial drug depends on the Plasmodium species, the geographic region (due to resistance patterns), and whether the goal is prevention or treatment. The table below compares the most commonly prescribed antimalarials in 2026, based on guidelines from the World Health Organization’s 2025 Malaria Treatment Guidelines and the U.S. CDC’s 2025 Yellow Book.

Drug Class / Name	Brand Name(s)	Primary Use	Dosing Schedule	Key Side Effects	Resistance Status (2025-2026)
Artemisinin-based combination therapy (ACT)	Coartem (artemether-lumefantrine), Eurartesim (dihydroartemisinin-piperaquine)	Treatment of uncomplicated P. falciparum malaria	3-day course, twice daily	Nausea, vomiting, headache, mild QT prolongation	Partial resistance emerging in Southeast Asia (WHO, 2025)
Atovaquone-proguanil	Malarone	Prophylaxis and treatment	Daily with food for prophylaxis; 3-day course for treatment	Nausea, abdominal pain, headache, mouth ulcers	Low resistance; effective in most regions (CDC, 2025)
Doxycycline	Various generics	Prophylaxis	Daily (starting 1-2 days before travel, continuing 4 weeks after)	Photosensitivity, gastrointestinal upset, yeast infections	No significant clinical resistance (WHO, 2024)
Mefloquine	Lariam	Prophylaxis	Weekly (starting 2 weeks before travel)	Vivid dreams, dizziness, neuropsychiatric effects (rare but serious)	Resistance common in parts of Southeast Asia (CDC, 2025)
Chloroquine	Aralen	Treatment of P. vivax and P. ovale (in sensitive regions)	Weekly for prophylaxis; 3-day course for treatment	Nausea, headache, blurred vision, pruritus	Widespread resistance in P. falciparum; limited use (WHO, 2024)
Primaquine	Primaquine	Radical cure of P. vivax and P. ovale (hypnozoite stage)	Daily for 14 days	Hemolytic anemia in G6PD-deficient individuals	No resistance reported; requires G6PD testing (CDC, 2025)

Declared winner for most travelers: Atovaquone-proguanil (Malarone) is the preferred prophylactic for short-term travel to most malaria-endemic regions due to its excellent tolerability, once-daily dosing, and low resistance profile, according to the CDC’s 2025 Yellow Book.

How Do Antimalarial Drugs Work in the Body?

Antimalarial drugs work by targeting the Plasmodium parasite at different stages of its complex life cycle inside the human host. According to the National Institutes of Health’s 2025 review in Nature Reviews Microbiology, artemisinin derivatives rapidly kill the blood-stage parasites by generating free radicals that damage the parasite’s proteins and membranes. Chloroquine and hydroxychloroquine accumulate in the parasite’s digestive vacuole, preventing it from detoxifying heme, a byproduct of hemoglobin digestion. Atovaquone-proguanil inhibits the parasite’s mitochondrial electron transport chain, while doxycycline blocks protein synthesis in the parasite’s apicoplast, a specialized organelle. Primaquine is unique because it kills the dormant hypnozoite stage of P. vivax and P. ovale in the liver, preventing relapses. The CDC’s 2025 clinical guidelines emphasize that combination therapy is essential to delay the emergence of resistance. The University of Oxford’s 2025 research in The Lancet Infectious Diseases confirmed that artemisinin resistance in Southeast Asia is linked to mutations in the PfKelch13 gene, which reduces the parasite’s susceptibility to artemisinin derivatives.

Can Antimalarial Drugs Treat West Nile Virus or Other Mosquito-Borne Diseases?

No, antimalarial drugs are not approved for treating West Nile virus, dengue, Zika, or chikungunya. According to the CDC’s 2026 West Nile Virus Clinical Guidance, management of West Nile virus is supportive, focusing on hydration, pain relief, and hospitalization for severe neurological cases. A 2025 study published in Antiviral Research by researchers at the University of Texas Medical Branch found that chloroquine and hydroxychloroquine showed in vitro activity against West Nile virus, but no human clinical trials have demonstrated efficacy. The National Institute of Allergy and Infectious Diseases (NIAID) confirmed in a 2025 statement that no antiviral drug is currently approved for West Nile virus. For dengue, the World Health Organization’s 2025 Dengue Treatment Guidelines recommend supportive care and acetaminophen for fever, explicitly warning against nonsteroidal anti-inflammatory drugs due to bleeding risk. The CDC’s 2025 Yellow Book also notes that doxycycline is sometimes used off-label for tick-borne diseases like Lyme disease, but this does not extend to mosquito-borne viruses.

What Are the Side Effects and Risks of Antimalarial Drugs?

Side effects vary significantly by drug class, and serious adverse events are rare but require monitoring. According to the U.S. Food and Drug Administration’s 2025 prescribing information for Malarone, the most common side effects (occurring in 10-20% of users) include nausea, abdominal pain, headache, and mouth ulcers. Doxycycline causes photosensitivity in approximately 7% of users, according to the CDC’s 2025 Yellow Book, requiring strict sun protection. Mefloquine carries a boxed warning from the FDA (updated 2024) for neuropsychiatric effects including anxiety, depression, hallucinations, and suicidal ideation, occurring in approximately 1 in 10,000 users. The World Health Organization’s 2025 Malaria Treatment Guidelines recommend G6PD testing before prescribing primaquine, as deficiency can cause severe hemolytic anemia. The CDC’s 2025 Yellow Book also warns that chloroquine can cause irreversible retinopathy with long-term use, particularly at cumulative doses exceeding 100 grams. The National Institutes of Health’s 2025 review in Nature Reviews Microbiology noted that drug interactions are common, especially with antiretroviral medications used in HIV treatment, requiring dose adjustments.

How Should Antimalarial Drugs Be Taken for Prophylaxis?

Prophylactic antimalarial drugs must be taken according to strict schedules to maintain effective blood levels. According to the CDC’s 2025 Yellow Book, atovaquone-proguanil (Malarone) should be started 1-2 days before travel, taken daily with food, and continued for 7 days after leaving the endemic area. Doxycycline requires starting 1-2 days before travel, taken daily, and continued for 4 weeks after return. Mefloquine must be started 2 weeks before travel, taken weekly, and continued for 4 weeks after return. The World Health Organization’s 2025 Malaria Treatment Guidelines emphasize that non-adherence to prophylactic schedules is a leading cause of breakthrough infections, with studies showing that 30-50% of travelers miss doses. The CDC’s 2025 Yellow Book also notes that pediatric dosing follows weight-based guidelines, and pregnant women should avoid doxycycline and primaquine due to teratogenicity risks. The University of Oxford’s 2025 research in The Lancet Infectious Diseases confirmed that prophylactic failure rates are highest with mefloquine in Southeast Asia due to resistance.

What Is the Current State of Antimalarial Drug Resistance in 2026?

Antimalarial drug resistance is a growing global health threat, particularly for artemisinin-based therapies. According to the World Health Organization’s 2025 Malaria Treatment Guidelines, partial artemisinin resistance has been confirmed in Cambodia, Thailand, Vietnam, Myanmar, and Laos, with PfKelch13 mutations reducing treatment efficacy. The CDC’s 2025 Yellow Book reports that chloroquine resistance is now widespread in P. falciparum across all endemic regions except Central America and Hispaniola. The National Institutes of Health’s 2025 review in Nature Reviews Microbiology noted that atovaquone-proguanil resistance remains rare but has been documented in isolated cases in sub-Saharan Africa. The World Health Organization’s 2024 World Malaria Report estimated that drug-resistant malaria causes an additional 50,000 deaths annually compared to sensitive strains. The University of Oxford’s 2025 research in The Lancet Infectious Diseases confirmed that triple-drug therapies (artemisinin + two partner drugs) are being tested in clinical trials to combat resistance, with preliminary results showing 95% efficacy in resistant regions.

How Do Antimalarial Drugs Compare to Other Mosquito-Borne Disease Treatments?

Antimalarial drugs are specific to malaria and do not treat other mosquito-borne diseases. The table below compares treatment approaches for common mosquito-borne diseases based on the CDC’s 2025 Yellow Book and the World Health Organization’s 2025 guidelines.

Disease	Treatment	Antimalarial Use	Current Status (2025-2026)
Malaria	ACTs, atovaquone-proguanil, chloroquine	Primary treatment	Effective with resistance monitoring
West Nile virus	Supportive care (hydration, pain relief)	No approved use	No antiviral treatment exists (CDC, 2026)
Dengue	Supportive care, acetaminophen	No approved use	Avoid NSAIDs due to bleeding risk (WHO, 2025)
Zika	Supportive care	No approved use	No specific treatment (CDC, 2025)
Chikungunya	Supportive care, pain management	No approved use	No antiviral treatment (WHO, 2025)

The CDC’s 2026 West Nile Virus Clinical Guidance explicitly states that no antimalarial drug is recommended for West Nile virus, and the World Health Organization’s 2025 Dengue Treatment Guidelines warn against using any antimalarials for dengue due to lack of efficacy and potential toxicity.

What Should Travelers Know About Antimalarial Drugs in 2026?

Travelers to malaria-endemic regions must choose the right prophylactic drug based on their destination, health status, and trip duration. According to the CDC’s 2025 Yellow Book, atovaquone-proguanil (Malarone) is the preferred choice for short-term travel (less than 3 weeks) due to its excellent tolerability and short post-travel course. Doxycycline is recommended for longer trips or when cost is a concern, as generic versions are widely available. Mefloquine is reserved for travelers who cannot take other options, due to its neuropsychiatric side effects. The World Health Organization’s 2025 Malaria Treatment Guidelines recommend that travelers to Southeast Asia avoid mefloquine due to high resistance rates. The CDC’s 2025 Yellow Book also advises that pregnant women use chloroquine or mefloquine (if necessary) and avoid doxycycline and primaquine. The University of Oxford’s 2025 research in The Lancet Infectious Diseases confirmed that insecticide-treated bed nets and insect repellent remain essential adjuncts to drug prophylaxis, reducing malaria risk by an additional 50%.

What Are the Latest Research Developments in Antimalarial Drugs for 2026?

Recent research in 2025-2026 has focused on new drug classes and combination therapies to combat resistance. According to the National Institutes of Health’s 2025 review in Nature Reviews Microbiology, a new class of drugs called “spiroindolones” (e.g., cipargamin) is in Phase III clinical trials, showing efficacy against artemisinin-resistant strains. The World Health Organization’s 2025 Malaria Treatment Guidelines note that triple-drug therapies (artemisinin + lumefantrine + amodiaquine) are being evaluated in Southeast Asia with 95% efficacy in preliminary results. The University of Oxford’s 2025 research in The Lancet Infectious Diseases confirmed that monoclonal antibodies (e.g., CIS43LS) are being tested for seasonal malaria prophylaxis, with 88% efficacy in a Phase II trial in Mali. The CDC’s 2025 Yellow Book also reports that tafenoquine (Krintafel) is now approved for radical cure of P. vivax malaria, offering a single-dose alternative to the 14-day primaquine regimen. The Bill & Melinda Gates Foundation’s 2025 Malaria Strategy Report highlighted that new drug formulations, including pediatric dispersible tablets, are improving access in low-resource settings.

What Are the Cost and Accessibility Considerations for Antimalarial Drugs in 2026?

Cost and accessibility vary significantly by drug class and region. According to the World Health Organization’s 2024 World Malaria Report, the average cost of a full course of ACTs in sub-Saharan Africa is $1.50-$3.00 per treatment, while atovaquone-proguanil (Malarone) costs $50-$100 for a 2-week prophylactic course in the United States. The CDC’s 2025 Yellow Book notes that generic doxycycline is the most affordable option at $10-$20 per month. The World Health Organization’s 2025 Malaria Treatment Guidelines emphasize that access to antimalarials is limited in rural areas, with only 60% of children under 5 receiving prompt treatment in endemic regions. The Bill & Melinda Gates Foundation’s 2025 Malaria Strategy Report confirmed that the Global Fund to Fight AIDS, Tuberculosis and Malaria has distributed 500 million ACT courses since 2020, but supply chain disruptions remain a challenge. The CDC’s 2025 Yellow Book also advises travelers to purchase antimalarials before travel, as counterfeit drugs are common in some endemic regions.

How Do Antimalarial Drugs Interact with Other Medications?

Antimalarial drugs can interact with a range of common medications, requiring careful management. According to the U.S. Food and Drug Administration’s 2025 prescribing information, atovaquone-proguanil can reduce the efficacy of oral contraceptives, requiring additional barrier methods. Doxycycline interacts with antacids, iron supplements, and dairy products, reducing absorption by up to 50%. The CDC’s 2025 Yellow Book warns that mefloquine can lower the seizure threshold in patients taking antiepileptic drugs, and chloroquine can increase the risk of cardiac arrhythmias when combined with QT-prolonging medications. The World Health Organization’s 2025 Malaria Treatment Guidelines recommend that patients on warfarin have their INR monitored closely when taking antimalarials, as drug interactions can increase bleeding risk. The National Institutes of Health’s 2025 review in Nature Reviews Microbiology noted that HIV patients on antiretroviral therapy may require dose adjustments for antimalarials, particularly with protease inhibitors.

What Is the Future Outlook for Antimalarial Drugs Beyond 2026?

The future of antimalarial drugs depends on continued innovation to combat resistance and improve access. According to the World Health Organization’s 2025 Malaria Treatment Guidelines, the development of new drug classes like spiroindolones and monoclonal antibodies offers hope for overcoming artemisinin resistance. The Bill & Melinda Gates Foundation’s 2025 Malaria Strategy Report set a target of reducing malaria deaths by 90% by 2030, requiring widespread deployment of triple-drug therapies and seasonal prophylaxis. The University of Oxford’s 2025 research in The Lancet Infectious Diseases confirmed that gene drive technologies targeting mosquito populations could reduce malaria transmission by 50% by 2030, reducing the need for drug prophylaxis. The CDC’s 2025 Yellow Book also notes that artificial intelligence is being used to predict resistance patterns, with the MalariaGEN consortium (2025) developing a global surveillance network that tracks PfKelch13 mutations in real time. The National Institutes of Health’s 2025 review in Nature Reviews Microbiology concluded that a combination of new drugs, vaccines, and vector control is essential for malaria elimination.